Inducing cell cycle arrest and apoptosis by dimercaptosuccinic acid modified Fe3O4 magnetic nanoparticles combined with nontoxic concentration of bortezomib and gambogic acid in RPMI-8226 cells

• Published in: International journal of nanomedicine Vol. 10; pp. 3275 - 3289
• Main Authors: Chen, Baoan, Wang, Fei, Zhang, Wei, Wang, Xinchao, Senthilkumar, Ravichandran, Qiao, Lixing
• Format: Journal Article
• Language: English
• Published: New Zealand Taylor & Francis Ltd 01.01.2015; Dove Press; Dove Medical Press
• Subjects: ABC transporters; Acids; Antineoplastic Agents - chemistry; Antineoplastic Agents - toxicity; Apoptosis; Apoptosis - drug effects; Biomedical materials; bortezomib; Bortezomib - chemistry; Bortezomib - toxicity; Cancer therapies; Cell cycle; Cell Cycle Checkpoints - drug effects; Cell Line, Tumor; Cytotoxicity; DMSA-Fe3O4; Drug delivery systems; Drug dosages; gambogic acid; Hematology; Humans; Hypoxia; Inhibitor drugs; Kinases; Laboratories; Leukemia; magnetic nanoparticles; Magnetite Nanoparticles - chemistry; Magnetite Nanoparticles - toxicity; Medical research; Multiple myeloma; Nanoparticles; NMR; Nuclear magnetic resonance; Original Research; Pharmaceuticals; PI3K/Akt; Proteins; Succimer - chemistry; Targeted cancer therapy; Xanthones - chemistry; Xanthones - pharmacology; United States > US; China; DMSA-Fe3O4; gambogic acid; cell cycle; apoptosis; bortezomib; magnetic nanoparticles; PI3K/Akt

The purpose of this study was to determine the potential benefits of combination therapy using dimercaptosuccinic acid modified iron oxide (DMSA-Fe3O4) magnetic nanoparticles (MNPs) combined with nontoxic concentration of bortezomib (BTZ) and gambogic acid (GA) on multiple myeloma (MM) RPMI-8226 cel...